- Conditions
- Multiple Sclerosis
- Interventions
- BG00002 (natalizumab), keyhole limpet hemocyanin (KLH), tetanus diphtheria toxoid vaccine (Td)
- Biological
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 10
- States / cities
- Fullerton, California • Centennial, Colorado • Farmington Hills, Michigan + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1921–1944
of 13,800
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma
- Interventions
- Carbon Ion Radiation Therapy (CIRT), Intensity Modulated Radiation Therapy (IMRT)
- Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- HIV Infections, Peripheral Nervous System Diseases, Pain
- Interventions
- Capsaicin Dermal Patch
- Drug
- Lead sponsor
- NeurogesX
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Berkeley, California • San Diego, California + 29 more
- Conditions
- Opioid-use Disorder, Opioid-related Disorders
- Interventions
- Not applicable - no defined intervention
- Other
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 534 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 35
- States / cities
- Haleyville, Alabama • Hamilton, Alabama • Little Rock, Arkansas + 30 more
- Conditions
- Fabry Disease
- Interventions
- agalsidase alfa
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- Not listed
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more
- Conditions
- Non-Cystic Fibrosis Bronchiectasis
- Interventions
- Brensocatib 10 mg, Brensocatib 25 mg, Placebo
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 12 Years to 85 Years
- Enrollment
- 1,767 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Conway, Arkansas • Little Rock, Arkansas + 61 more
- Conditions
- Mindfulness, Physical Activity
- Interventions
- Mindfulness, Heart-Rate
- Behavioral
- Lead sponsor
- Southern Methodist University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- BIOD-123, Lispro (Humalog)
- Drug
- Lead sponsor
- Biodel
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 34
- States / cities
- Anaheim, California • Chula Vista, California • Concord, California + 28 more
- Conditions
- Psoriasis
- Interventions
- ILV-094
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 15
- States / cities
- Beverly Hills, California • Santa Monica, California • South Miami, Florida + 9 more
- Conditions
- Chronic Liver Disease
- Interventions
- HepQuant SHUNT Liver Diagnostic Test
- Combination Product
- Lead sponsor
- HepQuant, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 26
- States / cities
- Chandler, Arizona • Coronado, California • Pasadena, California + 22 more
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose, Placebo
- Biological · Other
- Lead sponsor
- Uniquity One (UNI)
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 38
- States / cities
- Dothan, Alabama • Glendale, Arizona • Peoria, Arizona + 35 more
- Conditions
- HIV-1-infection
- Interventions
- ISL/LEN, B/F/TAF, PTM B/F/TAF, PTM ISL/LEN
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- LX3305, LX3305 Placebo, Methotrexate
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Childhood Embryonal Rhabdomyosarcoma, Childhood Malignant Ovarian Germ Cell Tumor, Endometrioid Stromal Sarcoma, Gestational Trophoblastic Tumor, Malignant Mesothelioma, Malignant Ovarian Epithelial Tumor, Melanoma, Neoplasm of Uncertain Malignant Potential, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Paget Disease of the Vulva, Recurrent Cervical Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage I Ovarian Cancer, Stage I Uterine Corpus Cancer, Stage I Vaginal Cancer, Stage I Vulvar Cancer, Stage IA Cervical Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Cervical Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage II Vaginal Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Cervical Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IV Uterine Corpus Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Uterine Corpus Cancer, Uterine Corpus Leiomyosarcoma, Vulvar Squamous Cell Carcinoma
- Interventions
- Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1992
- U.S. locations
- 187
- States / cities
- Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more
- Conditions
- Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation, RVOT Anomaly
- Interventions
- Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- Not listed
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2035
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 18 more
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Efimosfermin alfa, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 74
- States / cities
- Chandler, Arizona • Tucson, Arizona • Little Rock, Arkansas + 60 more
- Conditions
- Cytomegalovirus (CMV) Infection
- Interventions
- Letermovir oral granules, Letermovir tablet, Letermovir intravenous
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 11
- States / cities
- Duarte, California • Orange, California • San Francisco, California + 8 more
- Conditions
- Narcolepsy
- Interventions
- ADX-N05, Placebo
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 6 more
- Conditions
- Acne Vulgaris
- Interventions
- Doxycycline 0.6 mg/kg/day, Doxycycline 1.2 mg/kg/day, Doxycycline 2.4 mg/kg/day, Placebo
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 23
- States / cities
- Encino, California • Fremont, California • Los Angeles, California + 20 more
- Conditions
- Gastroesophageal Reflux Disease, Barrett's Esophagus, Esophagus Adenocarcinoma
- Interventions
- Primary Care Provider Survey, Gastroenterologist Survey, Patient Survey
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 725 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Philadelphia, Pennsylvania • Dallas, Texas
- Conditions
- Type 1 Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Insulin-Dependent, Juvenile Diabetes
- Interventions
- PROCHYMAL®, Placebo
- Drug
- Lead sponsor
- Mesoblast, Inc.
- Industry
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • La Jolla, California • Stanford, California + 17 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ABBV-155, Paclitaxel, Docetaxel
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Springdale, Arkansas • Orange, California + 17 more
- Conditions
- Alopecia Areata
- Interventions
- CTP-543
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
- Conditions
- Acne Vulgaris
- Interventions
- CD5789 (trifarotene) 50µg/g Cream, Placebo Cream
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 9 Years and older
- Enrollment
- 1,212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 26 more